8-K: Cardinal Health Soars in Q1 FY26, Raises Full-Year Outlook

Cardinal Health reported a strong first quarter for fiscal year 2026 with revenue up 22% and non-GAAP EPS up 36%, leading to a raised full-year guidance.

Summary

• First quarter fiscal year 2026 revenue increased 22% to $64.0 billion compared to Q1 FY25.
• GAAP operating earnings rose 18% to $668 million, and GAAP diluted EPS increased 11% to $1.88.
• Non-GAAP operating earnings surged 37% to $857 million, with non-GAAP diluted EPS up 36% to $2.55.
• All five operating segments contributed to segment profit growth.
• Fiscal year 2026 non-GAAP EPS guidance raised to $9.65 to $9.85, an increase of $0.35 from the prior range.
• Fiscal year 2026 non-GAAP adjusted free cash flow outlook raised to $3.0 billion to $3.5 billion.
• Anticipates completing the acquisition of Solaris Health in early November.

Sentiment

Score: 9

Explanation: The company reported significant revenue and earnings growth across all segments, substantially raised its full-year EPS and free cash flow guidance, and highlighted strategic investments and acquisitions. The overall tone and financial metrics are very strong.

Positives

• Revenue increased 22% to $64.0 billion in Q1 FY26.
• GAAP operating earnings increased 18% to $668 million.
• GAAP diluted EPS increased 11% to $1.88.
• Non-GAAP operating earnings increased 37% to $857 million.
• Non-GAAP diluted EPS increased 36% to $2.55.
• Segment profit growth was achieved across all five operating segments.
• Pharmaceutical and Specialty Solutions segment revenue increased 23% to $59.2 billion and segment profit increased 26% to $667 million.
• Global Medical Products and Distribution segment revenue increased 2% to $3.2 billion and segment profit increased by $38 million to $46 million.
• Other segment revenue increased 38% to $1.6 billion and segment profit increased 60% to $166 million.
• Raised fiscal year 2026 non-GAAP EPS guidance to $9.65 to $9.85 (from $9.30 to $9.50).
• Raised fiscal year 2026 non-GAAP adjusted free cash flow outlook to $3.0 billion to $3.5 billion (from $2.75 billion to $3.25 billion).
• Raised Pharmaceutical and Specialty Solutions segment profit growth outlook to 16% to 19% (from 11% to 13%).
• Raised Other segment profit growth outlook to 29% to 31% (from 25% to 27%).
• Sonexus Access and Patient Support business successfully onboarded over 30 new specialty therapies in Q1, supporting over 30% growth expectation for BioPharma Solutions in FY26.
• Opened a new state-of-the-art Consumer Health Logistics Center.
• Opened a new at-Home Solutions distribution center in Fort Worth, Texas.
• Initiated a $375 million accelerated share repurchase program in Q1 FY26.
• Net cash provided by operating activities significantly improved to $973 million in Q1 FY26 from $(1,647) million in Q1 FY25.
• Non-GAAP adjusted free cash flow significantly improved to $1,269 million in Q1 FY26 from $(1,361) million in Q1 FY25.

Negatives

• Effective Tax Rate increased to 24.1% from 23.0%.
• Interest and other expense outlook increased to ~$325 million from ~$275 million, reflecting financing costs for the Solaris Health acquisition.
• Total shareholders deficit increased slightly to $(2,731) million from $(2,634) million.

Risks

• Uncertainties associated with the pricing of branded pharmaceuticals, including legislative or executive actions.
• Risk of failing to achieve strategic objectives, such as the continued execution of the GMPD Improvement Plan initiatives, due to tariffs, an uncertain global economic environment, Cardinal Health Brand sales, or ongoing inflationary pressures.
• Competitive pressures in various lines of business, including the risk of customers reducing purchases or terminating/not renewing contracts due to price increases or other reasons.
• Risks associated with litigation matters, including a Department of Justice investigation focused on potential violations of the Anti-Kickback Statute and False Claims Act.
• Risk that events outside of control, such as weather or geopolitical events, may impact demand for products or cause supply shortages affecting cost and ability to fulfill customer demand.
• Performance of the generics program, including the amount or rate of generic deflation and the ability to offset it and maintain other financial and strategic benefits.
• Risks associated with recently completed and pending acquisitions, including those arising from entry into new lines of businesses.

Future Outlook

Cardinal Health has raised its fiscal year 2026 non-GAAP diluted EPS guidance to a range of $9.65 to $9.85, reflecting strong first-quarter performance and expected contributions from the Solaris Health acquisition. The company also increased its adjusted free cash flow outlook to $3.0 billion to $3.5 billion. Segment profit growth expectations for Pharmaceutical and Specialty Solutions and Other segments have also been raised. Interest and other expenses are expected to increase to ~$325 million due to financing costs for the Solaris Health acquisition, and capital expenditures are projected to be $600 million to $650 million.

Management Comments

• "We are pleased with our strong broad-based operational and financial performance to begin fiscal 2026."
• "This outstanding first quarter reflects our focused execution across each of our operating segments and provides a solid foundation as we carry forward."
• "As a result, we are raising our fiscal 2026 outlook."

Industry Context

The strong performance across all segments, particularly in Pharmaceutical and Specialty Solutions, suggests Cardinal Health is effectively navigating the dynamic healthcare distribution landscape. The focus on specialty therapies, logistics optimization, and at-home solutions aligns with broader industry trends towards specialized care, efficiency, and decentralized healthcare delivery. Acquisitions like Solaris Health and Advanced Diabetes Supply indicate strategic expansion into high-growth areas within healthcare services and products. The investment in new distribution centers with automation reflects an industry-wide push for supply chain resilience and technological advancement.

Legal Proceedings

• Department of Justice investigation focused on potential violations of the Anti-Kickback Statute and False Claims Act.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, raised guidance, and a $375 million accelerated share repurchase program, potentially leading to increased share value and returns.
• Employees: Potential for growth and stability due to strong company performance and strategic expansions, including new distribution centers.
• Customers: Improved service and efficiency through new distribution centers and logistics solutions (e.g., Consumer Health Logistics Center, OptiFreight Logistics).
• Suppliers: Continued business relationships, potentially expanded due to growth and acquisitions.
• Creditors: Increased confidence due to strong cash flow generation and improved financial health, though interest expense is rising due to acquisition financing.

Next Steps

• Completion of Solaris Health acquisition in early November.
• Webcast on October 30, 2025, at 8:30 a.m. ET to discuss first quarter results and fiscal year 2026 outlook.
• New Pharmaceutical and Specialty Solutions forward distribution center in Indianapolis expected to be fully operational by Fall 2027.
• Breaking ground on a new at-Home Solutions distribution center in Sacramento, California, this fiscal year, expected to be fully operational in Summer 2027.
• Continued execution of the GMPD Improvement Plan initiatives.

Key Dates

Recommendation

The company delivered exceptionally strong first-quarter results with significant revenue and non-GAAP EPS growth, driven by broad-based performance across all segments. The substantial increase in full-year non-GAAP EPS and adjusted free cash flow guidance, coupled with strategic acquisitions and investments in infrastructure, indicates robust operational momentum and a positive future trajectory. The accelerated share repurchase program further signals management's confidence and commitment to shareholder returns. Despite some increased financing costs, the overall financial health and growth prospects presented in the filing are highly favorable, making it a compelling investment opportunity.

Keywords

Pharmaceutical distribution, Specialty products, Medical products, Healthcare logistics, Supply chain, Earnings report, Financial results, Guidance, Acquisition, Share repurchase, Cardinal Health